Skip to Main Content
Contribute Try STAT+ Today

In a setback to efforts to control insulin prices, a U.S. court judge tossed key accusations made in a high-profile lawsuit filed by the Minnesota Attorney General accusing three drug makers of price gouging.

The lawsuit, which was filed in 2018, alleged that Eli Lilly (LLY), Novo Nordisk (NVO), and Sanofi (SNY) fraudulently set artificially high wholesale prices, but then negotiated lower prices by paying rebates and discounts to pharmacy benefit managers. In turn, pharmacy benefit managers create lists of medicines that receive preferred insurance coverage known as formularies. But the negotiations are confidential.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.